12:18 PM EDT, 05/02/2024 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q1 net loss Thursday of $0.69 per diluted share, narrower than a loss of $0.70 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.73.

Collaboration revenue for the quarter ended March 31 was $10.3 million, up from $9.5 million a year earlier.

Analysts surveyed by Capital IQ expected revenue of $13.1 million.

Kymera said that as of March 31 it had about $745 million in cash, cash equivalents, and investments, which it expects to provide it with a cash runway into H1 2027.

Price: 35.53, Change: -0.71, Percent Change: -1.96